CytoDyn (OTCMKTS:CYDY) Releases Quarterly Earnings Results

Key Points

• CytoDyn (OTCMKTS:CYDY) reported quarterly earnings of ($0.01) earnings per share, indicating a potential struggle in financial performance.
• The stock opened at $0.30 on Friday, with a twelve-month trading range between $0.10 and $0.49.
• CytoDyn is focused on developing treatments for multiple therapeutic areas, including COVID-19 and HIV, using their lead drug, leronlimab.

CytoDyn (OTCMKTS:CYDY - Get Free Report) posted its earnings results on Friday. The biotechnology company reported ($0.01) EPS for the quarter, Zacks reports.

CytoDyn Trading Up 0.7%

Shares of OTCMKTS CYDY traded up $0.00 during midday trading on Wednesday, reaching $0.28. 725,109 shares of the stock were exchanged, compared to its average volume of 2,863,857. CytoDyn has a 52-week low of $0.10 and a 52-week high of $0.49. The stock has a 50 day moving average price of $0.32 and a 200-day moving average price of $0.27. The company has a market capitalization of $344.17 million, a P/E ratio of 27.53 and a beta of 1.17.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.